Connection

THOMAS MONATH to Encephalitis Virus, Japanese

This is a "connection" page, showing publications THOMAS MONATH has written about Encephalitis Virus, Japanese.
Connection Strength

2.732
  1. Japanese Encephalitis: Risk of Emergence in the United States and the Resulting Impact. Viruses. 2023 12 28; 16(1).
    View in: PubMed
    Score: 0.892
  2. Analysis of ChimeriVax Japanese Encephalitis Virus envelope for T-cell epitopes and comparison to circulating strain sequences. Vaccine. 2007 Nov 19; 25(47):8077-84.
    View in: PubMed
    Score: 0.289
  3. Experimental infection of Culex annulirostris, Culex gelidus, and Aedes vigilax with a yellow fever/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE). Am J Trop Med Hyg. 2006 Oct; 75(4):659-63.
    View in: PubMed
    Score: 0.270
  4. Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines. J Virol. 2002 Feb; 76(4):1932-43.
    View in: PubMed
    Score: 0.196
  5. Japanese encephalitis vaccines: current vaccines and future prospects. Curr Top Microbiol Immunol. 2002; 267:105-38.
    View in: PubMed
    Score: 0.194
  6. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol. 2000 Feb; 74(4):1742-51.
    View in: PubMed
    Score: 0.170
  7. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology. 1999 May 10; 257(2):363-72.
    View in: PubMed
    Score: 0.162
  8. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine. 1999 Apr 09; 17(15-16):1869-82.
    View in: PubMed
    Score: 0.161
  9. Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants. J Infect Dis. 1990 May; 161(5):878-82.
    View in: PubMed
    Score: 0.087
  10. A single M protein mutation affects the acid inactivation threshold and growth kinetics of a chimeric flavivirus. Virology. 2007 Jun 05; 362(2):468-74.
    View in: PubMed
    Score: 0.069
  11. Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine. Vaccine. 2004 Sep 09; 22(27-28):3722-6.
    View in: PubMed
    Score: 0.059
  12. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis. 2003 Oct 15; 188(8):1213-30.
    View in: PubMed
    Score: 0.055
  13. Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J Virol. 2001 Jan; 75(2):934-42.
    View in: PubMed
    Score: 0.045
  14. Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14--14--2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes. Am J Trop Med Hyg. 2000 Apr; 62(4):480-4.
    View in: PubMed
    Score: 0.043
  15. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine. 2010 Jan 08; 28(3):632-49.
    View in: PubMed
    Score: 0.021
  16. Japanese encephalitis--a plague of the Orient. N Engl J Med. 1988 Sep 08; 319(10):641-3.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.